Back to Journals » Advances in Genomics and Genetics » Volume 5

BRAF mutation as a biomarker in colorectal cancer

Authors Varghese AM, Saltz L

Received 30 April 2015

Accepted for publication 13 July 2015

Published 15 October 2015 Volume 2015:5 Pages 347—353

DOI https://doi.org/10.2147/AGG.S87657

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Editor who approved publication: Dr John Martignetti

Anna M Varghese, Leonard B Saltz

Department of Medicine, Division of Solid Tumor Oncology, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Abstract: Nearly 10% of colorectal cancers (CRCs) harbor mutations in BRAF. While cytotoxic chemotherapy remains central to the treatment for patients with metastatic CRC, there is a growing understanding that CRC is comprised of molecularly and clinically distinct populations. BRAF-mutant CRC is one such subset. We are learning more about the complexity of BRAF-mutant CRCs and the ways in which patients with BRAF-mutant CRCs may or may not benefit from targeted therapies. This article reviews the role of BRAF as a biomarker in CRC and its implications for treatment.

Keywords: personalized medicine, colorectal cancer, BRAF
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]